Lung cancer is a malignant lung tumor characterized by uncontrolled cell growth in lung tissue with symptoms such as coughing, weight loss, fatigue and chest pain. The two types of lung cancers are small-cell lung carcinoma (SCLC) and non-small-cell lung carcinoma (NSCLC). The NSCLC type accounts for almost 80% of the cancers with NSCLC representing the remaining. The cure rates for the two types of lung cancers exchange their positions with the SCLC being the most malignant. The cure rates also depend on the stage of cancer detection with rates varying by 55% for first stage to just 1% for stage four.

Almost 85% of cases of Lung Cancer Therapeutics Market size are due to long-term tobacco smoking. Cigarette smoke contains at least 73 known carcinogens. Other factors causing lung cancer are genetic factors and exposure to triggers and carcinogens such as radon gas, asbestos, radioactive materials, second-hand smoke, or air pollution. It has also been demonstrated that passive smokers have a 20–30% increase in risk.
The treatments for lung cancer include surgery, chemotherapy, and radiotherapy with NSCLC responding better to surgery and SCLC usually responding better to chemotherapy and radiotherapy. The main drivers of stent lung cancer are the growing environmental pollution and smoking. The rise in the cases of lung cancers in females due to rising number of female smokers will drive the market up. Another driver is the greater screening rates with a sizable portion of lung cancer are detected during screening for other diseases.

Get Sample Report @ https://www.marketresearchfuture.com/sample_request/1185

Lung Cancer Market Players

• Hoffmann-La Roche Ltd (Switzerland)
• Novartis AG (Switzerland)
• Pfizer (U.S.)
• Merck Co., Inc. (U.S.)
• Bristol-Myers Squibb (U.S.)
• Eli Lilly and Company (U.S.)
• Sanofi (France)

among others are some key companies in the global Lung Cancer that are listed by MRFR for market research.

Regional Analysis:
The global market for Lung Cancer is growing steadily. The global lung cancer market on the basis of region comprises of North America, Europe, Asia Pacific and Middle East Africa. The global market for Lung Cancer is growing with the CAGR of 13.5% during the forecast period from 2017-2023. NSCLC is the most common type of lung cancer globally. The global Lung Cancer market reached USD 36929.8 million in 2023 from 15219.7 million in 2016. Europe region captured the second largest market globally and is expected to reach USD 8,536.3 million by 2023 due to the growing demand and need for lung cancer drugs, and the growing prevalence of lung cancer.

Global Lung Cancer Market has been segmented on the basis of:

• Types
  • Push button Lung Cancer
  • Pressure activated Lung Cancer
  • Side button Lung Cancer
• End user
  • Hospitals clinics
  • Diagnostic centers pathology laboratories
  • Home diagnostics
  • Other

Get Full Report @ https://www.marketresearchfuture.com/reports/lung-cancer-market-1185

1 Report Prologue

2 Introduction

2.1 Pipeline Development 15

2.2 Research Objective 21

2.3 Assumptions Limitations 22

2.3.1 Assumptions 22

2.3.2 Limitations 22

2.4 Market Structure 22

3 Research Methodology

3.1 Primary Research 24

3.2 Secondary Research 24

4 Porter’s Five Forces

4.1 Introduction 25

4.2 Bargaining Power Of Buyers 26

4.3 Bargaining Power Of Suppliers 26

4.3.1 Threat From Substitute 26

4.3.2 Threat From A New Entrant 26

4.3.3 Intensity Of Competitive Rivalry 26

TOC Continued…

About Market Research Future:

At Market Research Future (MRFR), we enable our customers to unravel the complexity of various industries through our Cooked Research Report (CRR), Half-Cooked Research Reports (HCRR), Consulting Services. MRFR team have supreme objective to provide the optimum quality market research and intelligence services to our clients.

Contact us:

Market Research Future (part of Wantstats Research and Media Private Limited),

99 Hudson Street, 5Th Floor,

New York, New York 10013

United States of America

+1 628 258 0071

Email: [email protected]